Abstract: A targeted drug delivery device comprises a brush for use in delivery of one or more therapeutic agents during surgical procedures, including but not limited to, heart, chest, abdominal, brain, limb, vascular, eye, organ transplantation surgery or cancer surgical treatment. The therapeutic agent is selected from the group consisting of genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals, drugs or biologics. Methods of treating diseases comprising delivering at least one therapeutic agent to a patient's organs or tissues using any one of the targeted drug delivery devices are disclosed.

Abstract: The present invention relates to a targeted cardiac therapy device that can precisely deliver therapeutic compounds to desired locations on, around or within the heart of a patient, and methods of treating conduction system disease, sinus node dysfunction, atrial fibrillation, myocardial infarction, and heart failure, using the described devices to deliver genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals and biologics.

Abstract: The present invention relates to a targeted cardiac therapy device that can precisely deliver therapeutic compounds to desired locations on, around or within the heart of a patient, and methods of treating conduction system disease, sinus node dysfunction, atrial fibrillation, myocardial infarction, heart failure, and muscular diseases with cardiac involvement, using the described devices to deliver genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals and biologics.

Abstract: In some aspects, the disclosure relates methods for identifying ventricular tachycardia in subjects, e.g., subjects who have previously experienced a myocardial infarction. In some embodiments, methods of the disclosure comprise measuring action potential durations and/or expression levels of KCNE3 and/or KCNE4 in a subject. In some aspects, the disclosure relates to methods and compositions for reducing or inhibiting the activity of KCNE3 and/or KCNE4, for example, in subjects having ventricular tachycardia.

Abstract: The present invention relates to a targeted cardiac therapy device that can precisely deliver therapeutic compounds to desired locations on, around or within the heart of a patient, and methods of treating conduction system disease, sinus node dysfunction, atrial fibrillation, myocardial infarction, and heart failure, using the described devices to deliver genetically engineered vectors or cells, proteins, stem cells, small molecule pharmaceuticals and biologics.